NMNH Advanced NAD+ Precursor 500mg 60 Capsules

An Important Note Before You Buy

This product is marketed under the term “NMNH,” which appears to refer to dihydronicotinamide mononucleotide — a compound related to, but distinct from, NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside), the two more commonly researched NAD+ precursors. NMNH has a considerably smaller research base than either NMN or NR, and we were unable to locate a clear ingredient panel, certificate of analysis, or independent verification of what this product actually contains beyond the manufacturer’s own marketing materials.

It’s worth knowing that neither NMN nor NMNH is currently authorised as a novel food in Great Britain or the EU — NR (nicotinamide riboside) is the only NAD+ precursor with that specific regulatory clearance, at a maximum of 300mg daily. This regulatory landscape is covered in more detail in our longevity supplements guide, though it’s worth noting that guide addresses NMN specifically — we can’t confirm where this product’s NMNH ingredient sits in relation to that same regulatory picture, and the marketing claims made for it (including specific multiples of effectiveness compared to other NAD+ precursors) aren’t something we can independently verify or endorse.

Given this uncertainty, we’d encourage anyone considering this product to contact the manufacturer directly for a full ingredient panel and any available safety or regulatory documentation before purchasing, and to speak to a GP before starting — particularly given how little independently verified information is available for this specific compound. This is not a product we can currently provide the same level of evidence-based guidance for as the rest of our NAD+ category.

The Research Behind This Product